Detalhe da pesquisa
1.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Artigo
Inglês
| MEDLINE | ID: mdl-37363867
2.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood
; 139(9): 1318-1329, 2022 03 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35108374
3.
Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature.
Ther Adv Neurol Disord
; 11: 1756285617753597, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-29403545
4.
Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia.
Onco Targets Ther
; 10: 645-656, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28223822
5.
Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges.
J Oncol Pract
; 13(6): 381-382, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28605617